Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Stemcells Inc (STEM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 20,000
  • Shares Outstanding, K 16,260
  • Annual Sales, $ 120 K
  • Annual Income, $ -36,420 K
  • 36-Month Beta 0.07
  • Price/Sales 170.94
  • Price/Cash Flow 0.00
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.25
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 12/05/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.70 +82.86%
on 10/31/16
1.74 -26.44%
on 11/16/16
+0.47 (+58.02%)
since 10/28/16
3-Month
0.70 +82.86%
on 10/31/16
1.74 -26.44%
on 11/16/16
-0.33 (-20.50%)
since 08/26/16
52-Week
0.33 +287.88%
on 06/24/16
6.72 -80.95%
on 12/01/15
-5.20 (-80.25%)
since 11/27/15

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Stemcells, Inc. is engaged in research aimed at the development of therapies that would use stem and progenitor cells derived from fetal or adult sources to treat, and possibly cure, human diseases and injuries such as Parkinson's disease, hepatitis, diabetes, and spinal cord injuries.

See More

Support & Resistance

2nd Resistance Point 1.63
1st Resistance Point 1.46
Last Price 1.28
1st Support Level 1.13
2nd Support Level 0.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.